PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 40.07
+0.47 (1.19%)
At close: Sep 23, 2026
SHE:301230 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 676.03 | 658.6 | 529.95 | 480.48 | 472.12 | 446.44 |
Other Revenue | 23.99 | 29.76 | 14.52 | 9.24 | 6.76 | 1.77 |
| 700.02 | 688.35 | 544.47 | 489.72 | 478.88 | 448.21 | |
Revenue Growth | 10.86% | 26.43% | 11.18% | 2.26% | 6.84% | 58.38% |
Cost of Revenue | 526.73 | 511.52 | 413.89 | 350.61 | 304.46 | 278 |
Gross Profit | 173.29 | 176.83 | 130.58 | 139.11 | 174.42 | 170.22 |
Selling, General & Admin | 114.08 | 111.01 | 89.18 | 73.59 | 80.17 | 61.87 |
Research & Development | 39.06 | 37.15 | 47.26 | 37.34 | 32.65 | 17.14 |
Other Operating Expenses | 2.86 | 2.01 | 1.76 | 1.24 | 1.66 | 1.77 |
Operating Expenses | 158.78 | 154.28 | 139.48 | 112.46 | 114.17 | 83.24 |
Operating Income | 14.51 | 22.55 | -8.9 | 26.64 | 60.25 | 86.98 |
Interest Expense | -7.71 | -8.29 | -9.28 | -5.46 | -4.79 | -2.53 |
Interest & Investment Income | 12.69 | 1.61 | 6.57 | 6.16 | 3.49 | 2.42 |
Currency Exchange Gain (Loss) | -5.24 | 0.88 | 5.37 | 0.7 | 9.44 | -2.56 |
Other Non Operating Income (Expenses) | -0.21 | -0.22 | -0.2 | -0.18 | -0.16 | -0.14 |
EBT Excluding Unusual Items | 14.04 | 16.53 | -6.44 | 27.86 | 68.23 | 84.17 |
Gain (Loss) on Sale of Investments | 12.48 | 7 | 4.97 | 5.58 | -0.1 | 0.4 |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | - | 0.01 | -0.07 | 0.05 |
Asset Writedown | -0.35 | -0.3 | -0.29 | -0.71 | - | -0.49 |
Other Unusual Items | 9.57 | 5.05 | 5.29 | 4.02 | 4.86 | 2.1 |
Pretax Income | 35.77 | 28.32 | 3.54 | 36.76 | 72.92 | 86.23 |
Income Tax Expense | -2.49 | -5.98 | -13.55 | -0.86 | 5.75 | 12.66 |
Net Income | 38.26 | 34.29 | 17.08 | 37.62 | 67.18 | 73.58 |
Net Income to Common | 38.26 | 34.29 | 17.08 | 37.62 | 67.18 | 73.58 |
Net Income Growth | 47.91% | 100.75% | -54.59% | -44.00% | -8.70% | 51.11% |
Shares Outstanding (Basic) | 180 | 178 | 185 | 181 | 144 | 136 |
Shares Outstanding (Diluted) | 187 | 186 | 185 | 181 | 144 | 136 |
Shares Change | 4.49% | 0.38% | 2.19% | 26.05% | 5.66% | 1.58% |
EPS (Basic) | 0.21 | 0.19 | 0.09 | 0.21 | 0.47 | 0.54 |
EPS (Diluted) | 0.20 | 0.18 | 0.09 | 0.21 | 0.47 | 0.54 |
EPS Growth | 41.57% | 100.00% | -55.56% | -55.57% | -13.59% | 48.83% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 102.44 | 92.2 | -28.54 | -227.41 | -24.67 | 13.01 |
Free Cash Flow Per Share | 0.55 | 0.50 | -0.15 | -1.26 | -0.17 | 0.10 |
Dividend Per Share | 0.231 | 0.285 | 0.331 | 0.195 | 0.211 | - |
Dividend Growth | -24.99% | -13.97% | 69.47% | -7.66% | - | - |
Gross Margin | 24.75% | 25.69% | 23.98% | 28.41% | 36.42% | 37.98% |
Operating Margin | 2.07% | 3.28% | -1.63% | 5.44% | 12.58% | 19.41% |
Profit Margin | 5.47% | 4.98% | 3.14% | 7.68% | 14.03% | 16.42% |
Free Cash Flow Margin | 14.63% | 13.39% | -5.24% | -46.44% | -5.15% | 2.90% |
EBITDA | 43.71 | 50.82 | 17.26 | 47.41 | 76.6 | 99.57 |
EBITDA Margin | 6.25% | 7.38% | 3.17% | 9.68% | 16.00% | 22.22% |
D&A For EBITDA | 29.21 | 28.27 | 26.16 | 20.77 | 16.35 | 12.59 |
EBIT | 14.51 | 22.55 | -8.9 | 26.64 | 60.25 | 86.98 |
EBIT Margin | 2.07% | 3.28% | -1.63% | 5.44% | 12.58% | 19.41% |
Effective Tax Rate | - | - | - | - | 7.88% | 14.68% |
Revenue as Reported | 700.02 | 688.35 | 544.47 | 489.72 | 478.88 | 448.21 |
Advertising Expenses | - | 0.07 | 0.21 | 0.11 | 0.43 | 0.03 |